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Abstract
Background: An increase in macular thickness due to fluid accumulation in the macula in patients with diabetes
mellitus. Optical coherence tomography (OCT) has been shown to be highly reproducible in measuring macular
thickness in normal individuals and diabetic patients. OCT can detect subtle changes of macular thickness. The aim
of this study is to compare central macular thickness (CMT) of diabetic patients with type 2 diabetes without clinical
retinopathy and normal controls, in order to assess possible increased macular thickness associated with diabetes
mellitus.
Methods: Optical coherence tomography (OCT) measurements were performed in 124 eyes of 62 subjects with
diabetes mellitus without clinically retinopathy (study group: 39 female, 23 male, mean age: 55.06 ± 9.77 years) and
in 120 eyes of 60 healthy subjects (control group: 35 female, 25 male, mean age: 55.78 ± 10.34 years). Blood
biochemistry parameters were analyzed in all cases. The data for central macular thickness (at 1 mm) and the levels
of the fasting plasma glucose and glycosylated hemoglobin (HbA1c) were compared in both groups.
Results: The mean central macular thickness was 232.12 ±24.41 μm in the study group and 227.19 ± 29.94 μm in
the control group.
The mean HbA1c level was 8.92 ± 2.58% in the study group and 5.07 ± 0.70% in the control group (p=0.001). No
statistically significant relationship was found between CMT, HbA1c, and fasting plasma glucose level in either
group (p=0.05).
Conclusions: Central macular thickness was not significantly thicker in patients with type 2 diabetes without
clinical retinopathy than in healthy subjects.






Diabetic retinopathy is the leading cause of blindness in
working aged adults in westernized countries. Diabetic
macular edema (DME) has been reported at rates of 10%
and occurs more frequently in type 2 diabetes mellitus than
in type 1. Diabetic patients also have multiple risk factors
for retinopathy, such as hyperglycemia and hypertension
[1]. Their visual acuity is often dependent the central foveal
involvement, perifoveal capillary blood flow velocity, sever-
ity of perifoveal capillary occlusion, and retinal thickness at
the central fovea [2,3]. The clinical findings of diabetic re-
tinopathy are microaneurysms, soft exudates, accumulation
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reproduction in any medium, provided the orMacular edema can develop at any stage of diabetic
retinopathy. In the past, macular edema was diagnosed
with slit-lamp view. Fundus fluorescein angiography pro-
vides guidance for treatment of macular edema. Optical
coherence tomography (OCT) has been used for detection
of macular edema secondary to different pathologies, such
as diabetes mellitus, central or branched retinal vein occlu-
sion, uveitis, and age related macular degeneration [4–11].Methods
The central macular thickness (CMT) was measured in
both groups by OCT (Optovue Inc. Co., RTVue 100 model,
Fremont, CA). The CMT was measured after providing
pupil dilation with tropicamide drops 2 times, 10 minutes
before measurement (Tropicamide 1%, Alcon Lab. Inc,
USA). Three measurements were taken from each patienttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic characteristics, values for central macular thickness (CMT), and biochemical analysis in patients
with type 2 diabetes without clinical retinopathy
Parameters Study group (n=62) Control group (n=60) p
BCVA 0.00 (log MAR) 0.00 (logMAR) NS
IOP mmHg 17,8 ±2.3 mmHg 18.1 ±2.1 mmHg NS
Age(year) 55.06±9.77 55.78±10.34 NS
Male/Female Gender 23/39 25/35 NS
CMTμm(±SD) 232.12±24.41 227.19±29.94 NS
HbA1c ( mean±SD) 8.92±2.58 5.07±0.70 0.001
Fasting blood glucose Average ±SD 202.14±104.78 (median:178 ) 92.17±7.75 (median:92) 0.001
BCVA: Best corrected visual acuity, IOP: Intraocular pressure, CMT: Central macular thickness, μm:micrometer, SD: standard deviation, logMAR: logarithm of the
minimum angle of resolution, HbA1c: glycosylated hemoglobin, n: number of patients, logMAR: logarithm of the minimum angle of resolution, NS: Non significant;
Study group: Patients with type 2 diabetes without clinical retinopathy; Control group: healthy controls.
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after pupillary dilatation. Blood biochemical tests for
glycosylated hemoglobin (HbA1c) and fasting plasma
glucose levels were run on all patients. All cases under-
went ophthalmological examinations including best
corrected visual acuity (BCVA), anterior and posterior
segment examinations under slit-lamp, intraocular pres-
sure (IOP) (applanation tonometer model AT 900;
Haag-Streit, Switzerland), and central macular thickness
measured by OCT Visual acuity was measured with an
Early Treatment Diabetic Retinopathy Study chart at 4
meters. Each subject gave written informed consent to
participate in the study. Ethic Committee approval was
obtained from local committee.
Participiants
The study group included 62 patients (124 eyes; 39
female, 23 male, mean age: 55.06 ± 9.77 years) who had
type 2 diabetes mellitus without clinical retinopathy and
a control group of 60 patients (120 eyes; 35 female, 25
male, mean age: 55.78 ± 10.34 years) (Table 1). Inclusion
criteria for the study group included: no visible findings of
diabetic retinopathy (hard-soft exudates, microaneurysms)
on retina at slit-lamp fundus examination with a +78 D
lens, type 2 diabetes mellitus, no other problems (such as
hypertension, uveitis), and no history of ophthalmologic
trauma, intravitreal injection, high refractive errors (sphe-
rical equivalent; between: +1.00 D to −1.00 D) or use of
RA
CT
ETable 2 Duration and treatment of diabetes mellitus in
patients with type 2 diabetes without clinical retinopathy
Duration of DM n (=62) %
New diagnosis 5 8.1
1-5 years 19 30.6
6-10 years 23 37.1
11-15 years 9 14.5
>15 years 6 9.7
Insulin treatment 49 79
OAD (oral anti-diabetic drug) 8 12.9
DM: Diabetes mellitus, n: number of patients.
RE
Tdrugs(s) for retinal problems. Inclusion criteria for the
control group patients included: no ophthalmologic or
systemic problems, no history of intraocular surgery or
treatment of the retina, and no high refractive errors
(spherical equivalent: between −1.0 D to +1.0 D). Exclu-
sion criteria for both groups were visible retinopathy or
uveitis, hypertension, or previous ophthalmologic surgery.
In the study group, the duration of diabetes mellitus
ranged from 0 – 20 years and the average was 7.19 ± 4.87
years. Five patients were newly diagnosed, 19 patients had
been diagnosed for 1–5 years, 23 patients had been diag-
nosed for 6–10 years, 9 patients had been diagnosed for
11–15 years, and 6 patients had been diagnosed for more
than 15 years. In the study group; five patients were newly
diagnosed, 49 patients were undergoing insulin treatment,
and 8 patients were taking oral antidiabetic drugs (Table 2).
Both groups were compared based on mean age, central
macular thickness, fasting plasma glucose, and HbA1c levels.
Statistical analysis
The NCSS (Number Cruncher Statistical System) 2007
and the PASS 2008 Statistical Software (Utah, USA) pro-
grams were used to evaluate the results of the study.
Descriptive statistical methods (mean, standard de-
viation) and Student’s t- test were used together to com-
pare the data from the two groups and the parameters




CTable 3 Relationship between central macular thickness
(CMT), glycosylated hemoglobin (HbA1c), and fasting










r p r p
CMT-HbA1c −0.077 NS 0.001 NS
CMT-Fasting glucose level −0.091 NS 0.011 NS
CMT: Central macular thickness, HbA1c: glycosylated hemoglobin, p; statistic
value, r: relation between two variables.
NS: Non significant; Study group: Patients with type 2 diabetes without clinical
retinopathy; Control group: healthy controls.
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that did not show normal distribution. A Chi-square test
was used to compare the quality of the data. Pearson
correlation analyses were conducted to evaluate the rela-
tionship between the parameters showing normal distri-
bution and Spearman’s rho correlation analyses have
been used to evaluate correlation between the parame-
ters not showing normal distribution. A value of p<0.05
was considered significant.
Results
Best corrected vision (BCVA) was 0.00 (log MAR) in
both groups. No significant differences were found for
the mean age, IOP, or gender distribution (Table 1).
The mean HbA1c level was 8.92 ± 2.58% in the study
group, and 5.07 ± 0.70% in the control group. The mean
level of HbA1c was statistically higher in the study group
than in the control group (Table 1, p=0.001). Fasting
plasma glucose level was statistically higher in the study
group than in the control group (Table 1, p=0.01). The
duration of diabetes mellitus was 7.19 ± 4.8 (range: 0–
20) years. The mean of CMT was 232.12 ± 24.41 μm in
the study group and 227.19 ± 29.94 μm in the control
group (Table 1). The CMT was thicker in the study
group than in the control group but this difference was
not statistically significant.
No relationship was found between CMT and fasting
plasma glucose level in the study (p=0.483) and control
(p=0.399) groups. No relationship was found between
CMT and HbA1c level in the study (p=0.550), and con-
trol (p=0.997; Table 3).
Discussion
We found no studies in the literature which reviewed
CMT, fasting plasma glucose level, and level of HbA1c
less than HbA1c 8%.
Several previous studies [12–17] determined that optical
coherence tomography can help in the evaluation of macu-
lar edema in diabetic or non-diabetic patients, and also
help in the follow-up of the patients during treatment to
establish quantitative or qualitative responses to therapy.
We reviewed the relationship between central macular
thickness, HbA1c, and fasting plasma glucose levels in pa-
tients with type 2 diabetes without clinical diabetic retino-
pathy. Optical Coherence Tomography (OCT) was used
for objective measurement and monitoring of central
macular thickness. Browning and Hee, et al. [18,19] de-
scribed that a change in the OCT measurements greater
than 10% of the baseline thickness is likely to represent a
true change in macular thickness. Glycosylated hemoglobin
is a parameter that can be used to follow up hyperglycemia
over the long term. Moon, at al [20] suggested that a high
baseline HbA1c and a large reduction in HbA1c were risk




TEshowed that HbA1c level positively correlated with macu-
lar thickness in patients with type1 and 2 diabetes of10 or
more years’ duration without diabetic macular edema.
Chou, Moreira at al [22]. showed that a HbA1c level of 8%
or above was associated with an increase in macular thick-
ness in diabetic patients with diabetic retinopathy. Yeung,
at al. [21–23] concluded that meticulous diabetes control
may slow the progression of early diabetic retinopathy and
may play an important role in preventing macular dysfunc-
tion. In type 1 and 2 diabetes patients, strict follow-up of
plasma glucose level could reduce the progression and de-
velopment of diabetic retinopathy.
The purpose of this study was to examine central macu-
lar thickness in patients with type 2 diabetes mellitus with-
out retinopathy. This study showed the following four
results: 1) The mean central macular thickness is thicker
in diabetic patients without diabetic retinopathy than in
healthy subjects, but this difference was not statistically
significant; 2) No positive relationship was found between
fasting plasma glucose level and the central macular thick-
ness in patients with diabetes mellitus without retino-
pathy; 3) Central macular thickness was not increased by
mild or high levels of HbA1c (8.92 ± 2.59%); and 4) Cen-
tral macular thickness was not affected by the duration of
diabetes mellitus in patients with diabetes type 2 without
retinopathy. There are limitations to our study. One of
these is the small sample size in both groups and ano-
ther is that no patients had diabetes mellitus for longer
than 20 years.
Conclusion
Our opinion is that the truly effective parameter on
macular thickness is vascular permeability in patients
with diabetes mellitus.
In this study, glycosylated HbA1c and fasting plasma
glucose levels were significantly higher in diabetic patients
without retinopathy than in the control group, although
there was no difference in central macular thickness be-
tween the two groups.
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